- Home
- DNLI
as 04-18-2025 1:34pm EST
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.8B | IPO Year: | 2017 |
| Target Price: | $37.57 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.57 - $33.33 | Next Earning Date: | 05-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 372.05% |
Latest Denali Therapeutics Inc. News
DNLI Breaking Stock News: Dive into DNLI Ticker-Specific Updates for Smart Investing
Zacks
16 days ago
DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up
MT Newswires
17 days ago
Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up
GlobeNewswire
17 days ago
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
Zacks
a month ago
Why You Shouldn't Bet Against Denali (DNLI) Stock
MT Newswires
a month ago
B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating
TipRanks
2 months ago
Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer
Insider Monkey
2 months ago
Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?
MT Newswires
2 months ago
Oppenheimer Adjusts Denali Therapeutics Price Target to $42 From $50, Maintains Outperform Rating
Compare DNLI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DNLI Denali Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.